UTHR UNITED THERAPEUTICS Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1082554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.9%
TTM net income YoY-3.2%
TTM EPS YoY0.4%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR11.0%
Margins
Gross margin86.3%
Operating margin41.4%
Net margin38.6%
FCF margin27.2%
EBITDA margin44.5%
Returns
ROE19.1%
ROA17.1%
ROIC (approx.)20.9%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets10.8%
Debt / equity0.00x
Current ratio4.61x
Interest coverage111.02x
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue17.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.18B | $2.88B |
| Cost of revenue | $384.40M | $309.70M |
| Gross profit | $2.80B | $2.57B |
| R&D expense | $550.00M | $481.00M |
| SG&A expense | $755.80M | $709.70M |
| Operating income | $1.49B | $1.38B |
| Interest expense | $19.50M | $42.90M |
| Pretax income | $1.71B | $1.54B |
| Income tax | $379.20M | $343.90M |
| Net income | $1.33B | $1.20B |
| EBITDA | $1.58B | $1.45B |
| EPS (basic) | 30.13 | 26.44 |
| EPS (diluted) | 27.86 | 24.64 |
| Weighted avg. shares (diluted) | 47.90M | 48.50M |
| Balance sheet | ||
| Cash & equivalents | $1.56B | $1.70B |
| Short-term investments | $1.36B | $1.57B |
| Receivables | $350.20M | $279.30M |
| Inventory | $183.10M | $157.90M |
| Current assets | $3.70B | $3.87B |
| PP&E, net | $1.73B | $1.22B |
| Goodwill | $32.30M | $32.30M |
| Total assets | $7.88B | $7.36B |
| Current liabilities | $560.60M | $738.10M |
| Total liabilities | $783.80M | $920.00M |
| Shareholders' equity | $7.10B | $6.44B |
| Shares outstanding | 43.64M | 44.83M |
| Cash flow statement | ||
| Operating cash flow | $1.56B | $1.33B |
| Capital expenditure | $520.50M | $246.50M |
| Free cash flow | $1.04B | $1.08B |
| Investing cash flow | -$551.30M | $417.20M |
| Financing cash flow | -$1.15B | -$1.25B |
| Depreciation & amortization | $85.60M | $72.50M |
| Stock-based compensation | $147.70M | $144.00M |
| Share buybacks | $1.00B | $1.00B |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.